구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Efineptakin alfa |
Overview Company | NeoImmuneTech |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Refractory Diffuse Large B-cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model.. Despite recent advancements in immunotherapy, most cancer patients still struggle to achieve sustained benefits, highlighting the need for new treatment strategies. In the past, lack of available models to assess immunotherapeutic combinations hampered development. In this new study, w… |
Toxicology CRS | Reported |
Clinical Safety signal | NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model.. Despite recent advancements in immunotherapy, most cancer patients still struggle to achieve sustained benefits, highlighting the need for new treatment strategies. In the past, lack of available models to assess immunotherapeutic combinations hampered development. In this new study, w… |
Clinical Selected reported efficacy | ORR 6% |
Clinical Reported ORR | 6% |
Clinical Result source | ClinicalTrials.gov NCT04984811 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04984811 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Efineptakin alfa |
Overview Company | NeoImmuneTech |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Refractory Diffuse Large B-cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model.. Despite recent advancements in immunotherapy, most cancer patients still struggle to achieve sustained benefits, highlighting the need for new treatment strategies. In the past, lack of available models to assess immunotherapeutic combinations hampered development. In this new study, w… |
Toxicology CRS | Reported |
Clinical Safety signal | NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model.. Despite recent advancements in immunotherapy, most cancer patients still struggle to achieve sustained benefits, highlighting the need for new treatment strategies. In the past, lack of available models to assess immunotherapeutic combinations hampered development. In this new study, w… |
Clinical Selected reported efficacy | ORR 6% |
Clinical Reported ORR | 6% |
Clinical Result source | ClinicalTrials.gov NCT04984811 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04984811 |
추천 비교
추천 비교